BioMarin is currently seeking patients for a Phase 3 clinical trial in Late Onset Pompe Disease.
This phase 3 study incorporates a switchover design in which all patients switch directly from Myozyme® or Lumizyme®1 to the experimental drug BMN 701 without missing doses, to determine if patients currently on enzyme replacement therapy with Myozyme® or Lumizyme® can improve more in measures of respiratory muscle strength, muscle weakness and endurance.
Clinicaltrials.gov identifier: www.clinicaltrials.gov/ct2/show/NCT01924845
Travel Information: Patients will not be required to spend their own money for study related travel. The trial related travel costs, including hotels, car rentals/taxis, airfare/train fare, mileage, food and any other approved trial related expenses will be paid by BioMarin. Arrangements will also be made for special travel needs, such as wheelchair accessible taxis and hotel rooms as well as transportation through the airport terminal.
1Myozyme and Lumizyme are registered trademarks of Genzyme, a Sanofi Company
Disclaimer: The IPA does not endorse any of the products, medications, treatments or information reported herein. Articles on the IPA web pages are intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.